A. Yonezawa

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Yonezawa, A. Yonezawa, Atsushi Yonezawa
Publication record
158 papers · 4,750 citations · H-index 32

PAPERS

Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration.
20231 citationsauthor #4
Abstract P2-26-07: Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study (KBCRN-A002 study)
20230 citationsauthor #18
A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis
202312 citationsauthor #9
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
20238 citationsauthor #13
Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.
20231 citationsauthor #2
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
20239 citationsauthor #17
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure
20233 citationsauthor #9
Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder
202219 citationsauthor #9
Examination of the Bleeding Risk Involved in the Concomitant Use of Antidepressants and Direct Oral Anticoagulants
20220 citationsauthor #7
Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation
202211 citationsauthor #8
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody
20220 citationsauthor #5
A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics
20224 citationsauthor #5
Therapeutic Drug Monitoring of Antibody Drugs.
20226 citationsauthor #1
Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study
20229 citationsauthor #7
ロフラゼプ酸エチル活性代謝物の褥婦母乳およびその児の血中濃度を測定した2症例
20220 citationsauthor #2
3. Proper Use and Issues of Biosimilars for Future Expansion of Use
20220 citationsauthor #1
Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics
20226 citationsauthor #6
N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4
20220 citationsauthor #2
Improved absorption of itraconazole tablet by co-administration with lemon beverages in a lung transplant recipient: A case report.
20222 citationsauthor #6
Effect of Itraconazole and Its Metabolite Hydroxyitraconazole on the Blood Concentrations of Cyclosporine and Tacrolimus in Lung Transplant Recipients.
20224 citationsauthor #6
Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.
20226 citationsauthor #2
Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis
20223 citationsauthor #8
STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma
20222 citationsauthor #10
A Nationwide Questionnaire Survey on Awake Craniotomy in Japan
20226 citationsauthor #11
Factors associated with somnolence during brain function mapping in awake craniotomy.
20213 citationsauthor #8
MicroRNA-101 Regulates 6-Hydroxydopamine-Induced Cell Death by Targeting Suppressor/Enhancer Lin-12-Like in SH-SY5Y Cells
20213 citationsauthor #9
Pharmacist-physician collaborative care for outpatients with left ventricular assist devices using a cloud-based home medical management information-sharing system: a case report
20211 citationsauthor #2
Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case–control study
202130 citationsauthor #4
Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients.
20216 citationsauthor #4
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
202124 citationsauthor #9
Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction
202116 citationsauthor #3
Complete Deletion of Slc52a2 Causes Embryonic Lethality in Mice.
20214 citationsauthor #3
Antibiotic-induced microbiome depletion alters renal glucose metabolism and exacerbates renal injury after ischemia-reperfusion injury in mice.
202120 citationsauthor #8
Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxis.
20218 citationsauthor #9
Recent advances in riboflavin transporter RFVT and its genetic disease.
202121 citationsauthor #2
Pronociceptive Roles of Schwann Cell–Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy
202126 citationsauthor #13
Abstract P3-09-07: A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative metastatic breast cancer (KBCRN-B-002 trial)
20201 citationsauthor #18
Personalized therapy of biological medicines -TDM of monoclonal antibodies-
20200 citationsauthor #1
Challenge and future prospective of biosimilars
20200 citationsauthor #1
Therapeutic Outcome of Inhalation-support Team Collaboration with Hospital and Community Pharmacists
20201 citationsauthor #3
Facilitation of Schwann cell differentiation can be a novel approach to suppress paclitaxel-induced peripheral neuropathy
20200 citationsauthor #6
Effects of low‐dose remifentanil infusion on analgesic or antiemetic requirement during brain function mapping: A retrospective cohort study
20204 citationsauthor #12
Prevalence of and risk factors for adverse events in Alzheimer’s patients receiving anti-dementia drugs in at-home care
202013 citationsauthor #5
Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses
20200 citationsauthor #10
Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection.
20203 citationsauthor #9
[Current Issues and Future Perspectives of Biosimilar in Cancer Therapy].
20202 citationsauthor #1
Schwann cell-derived CXCL1 contributes to human immunodeficiency virus type 1 gp120-induced neuropathic pain by modulating macrophage infiltration in mice.
202023 citationsauthor #9
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses
20207 citationsauthor #10
Abstract P4-10-33: Alteration of the tumor immune microenvironment signatures by nivolumab combined with radiation therapy for patients with metastatic breast cancer (Translational Research of the KBCRN-B-002 trial)
20200 citationsauthor #11
Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of l-dopa and its metabolite 3-O-methyldopa in combination with entacapone
20204 citationsauthor #6
Effect of riboflavin deficiency on development of the cerebral cortex in Slc52a3 knockout mice
202014 citationsauthor #2
Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
201920 citationsauthor #4
Acceleration of nano‐surface and molecular‐orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab
201910 citationsauthor #2
Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report
20191 citationsauthor #2
Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
201918 citationsauthor #5
A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype
20199 citationsauthor #6
Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C.
20192 citationsauthor #2
Add-on effects of tadalafil for tamsulosin-treated patients with benign prostatic hyperplasia suffering from residual lower urinary tract symptoms: a randomized, placebo-controlled, double-blind, crossover study
20190 citationsauthor #8
Role of ubiquitin ligase HRD1 in a cellular model of Parkinson's disease
20180 citationsauthor #7
Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum
201811 citationsauthor #4
Kobe University Repository : Kernel タイトル Tit le Populat ion Pharmacokinet ics of Topiramate in Japanese Pediatric and Adult Pat ients With Epilepsy Using Rout inely Monitored Data
20180 citationsauthor #6
Pharmacokinetics and Pharmacodynamics of Therapeutic Monoclonal Antibodies for Personalized Medicine
20180 citationsauthor #1
Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation
20188 citationsauthor #10
Epidemiology and Risk Factors of Drug-Induced Lung Disease: What Are the Prevalence and Risk Factors of DILD?
20182 citationsauthor #2
Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells.
20185 citationsauthor #8
Biomarkers to predict the efficacy of Infliximab in the Patients with Inflammatory Bowel Disease
20180 citationsauthor #2
Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery
20188 citationsauthor #12
Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis
201820 citationsauthor #12
Relationship between plasma concentration and efficacy of rituximab in the patient with non-Hodgkin's lymphoma
20180 citationsauthor #2
How to Manage Drug Interactions in Clinical Settings (2)
20180 citationsauthor #6
A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model
201829 citationsauthor #5
Disruption of Slc52a3 gene causes abnormalities of energy metabolism and brain development in mice with riboflavin deficiency
20180 citationsauthor #3
Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.
201814 citationsauthor #7
Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
20183 citationsauthor #3
How to Manage Drug Interactions in Clinical Settings (1)
20181 citationsauthor #6
CYP 2 C 19 polymorphism affects the efficacy but not drowsiness in the low dose clobazam therapy
20180 citationsauthor #6
Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts
20187 citationsauthor #8
How to Manage Drug Interactions in Clinical Settings (3)
20180 citationsauthor #2
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.
201814 citationsauthor #7
Application of nSMOL coupled with LC‐MS bioanalysis for monitoring the Fc‐fusion biopharmaceuticals Etanercept and Abatacept in human serum
201815 citationsauthor #4
Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
201781 citationsauthor #7
Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data
20176 citationsauthor #6
Title Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss : a prospective clinical trial
20170 citationsauthor #14
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia
201719 citationsauthor #8
Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane.
201718 citationsauthor #3
Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
20170 citationsauthor #7
Clinical Pharmacology of Therapeutic Antibodies for Precision Medicine
20170 citationsauthor #1
TDM of infliximab by LC-MS/MS using nSMOL in patients with inflammatory bowel disease
20170 citationsauthor #1
A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head
201646 citationsauthor #4
Abstract B082: Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody- dependent cellular cytotoxicity against colorectal cancer cell lines
20160 citationsauthor #4
Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
20166 citationsauthor #1
LC/QTOF‐MSによるフィルグラスチムバイオ後続品の定性・成分分析
20160 citationsauthor #4
Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice
201630 citationsauthor #2
Abstract 2318: Discovery and validation of a novel checkpoint target preferentially expressed in the tumor microenvironment
20160 citationsauthor #7
Protocol for Unrequired Inquiries about the Prescription to Doctors under the Agreement between the Hospital and Community Pharmacies
20165 citationsauthor #11
Abstract 1401: A systems immunology analysis to detect prognostic biomarkers in patients with squamous cell carcinomas of the head and neck
20160 citationsauthor #3
Clinical Outcomes of Vancomycin Therapy by the Protocol-Based Pharmacotherapy Management (PBPM) including TDM-Order: ～TDMオーダを含めたバンコマイシン処方設計支援～
20162 citationsauthor #8
Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia
201656 citationsauthor #6
Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data
201625 citationsauthor #6
Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury
201511 citationsauthor #8

TIMELINE

2003 202 citations

2004 42 citations

2005 238 citations

2006 723 citations

2007 250 citations

2008 214 citations

2009 76 citations

2010 524 citations

2011 455 citations

2012 189 citations

2013 578 citations

2014 222 citations

2015 206 citations

2016 170 citations

2017 124 citations

2018 137 citations

2019 60 citations

2020 72 citations

2021 162 citations

2022 78 citations

2023 34 citations

A. Yonezawa

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT